Associate Professor of Medicine, Dana-Farber Cancer Institute
Oncology
Dr. Harold J. Burstein, MD
|
|
Give Review
Harold Burstein is an expert in the field of Oncology. He went to medical school at Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. He over the years received 6 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "Boston Magazine", "Fellow (FASCO)", "Whos Who in Medicine and Healthcare" and "Super Doctor". Harold J. Burstein is a published doctor. He published 98 publications, including: 'Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
- Adjuvant endocrine therapy for postmenopausal women: Type and duration.
- Clinical Cancer advances 2015: annual report on progress against Cancer from the american society of clinical oncology.
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive Breast cancer.
- Adjuvant Ovarian Suppression in Premenopausal Breast Cancer.
- Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study.
- Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer.
- Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB...
- Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
- Use and duration of chemotherapy in patients with metastatic Breast cancer according to tumor subtype and line of therapy.
- Personalized medicine in Breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
- Patients with triple negative Breast cancer: Is there an optimal adjuvant treatment?
- Clinicopathological features among patients with advanced human epidermal growth factor-2-positive Breast cancer with prolonged clinical benefit to first-line trastuzu...
- Breast cancer treatment in the era of individualized care.
- Expert opinion vs guideline based care: The St. Gallen Case study.
- Breast Cancer, Version 3.2013.
- A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic Breast cancer.
- Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic Breast cancer in the post-trastuzumab era.
- High performance teamwork training and systems redesign in outpatient oncology.
- Combination antiangiogenic therapy in advanced Breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet ...
- Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates.
- JNCCN Reaches 10.
- Avastin for Breast cancer, 2005-2011: requiescat in pacem?
- The continuity of care checklist: a critical frontier in patient safety.
- Have we been down this road before?
- Peek before you treat? Is it a fantasy or reality?
- American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays.
- The Fifth "C" Is Cost: Highlights From ASCO 2011.
- Radiation therapy for ductal Carcinoma in situ: A decision analysis.
- Novel agents and future directions for refractory Breast cancer.
- Introduction: Current and future approaches to chemotherapy in patients with resistant Breast cancer.
- Texting the doctor.
- Contrary Effects of the Receptor Tyrosine Kinase Inhibitor Vandetanib on Constitutive and Flow-Stimulated Nitric Oxide Elaboration in Humans.
- Bevacizumab for advanced Breast cancer: all tied up with a RIBBON?
- Congestive heart failure risk in patients with Breast cancer treated with bevacizumab.
- Take your medicine.
- Invasive Breast cancer.
- Beaten at the alamo by the europeans.
- Breast cancer: noninvasive and special situations.
- Board recertification.
- American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive Breast cancer.
- Addressing oncology pharmacy & policy.
- Cardiac toxicity from systemic Cancer therapy: a comprehensive review.
- Avastin, ODAC, and the FDA: are we drafting the right players?
- Adjuvant hormonal therapy for early-stage Breast cancer.
- Re-engineering the cooperative groups.
- Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive Breast cancer.
- Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic Breast cancer.
- Refining therapy for human epidermal growth factor receptor 2-positive Breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.
- Screening contretemps: the real issue in the mammogram guideline debate.
- What is a patient navigator, and should we have them in major Cancer centers?
- Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active Cancer treatment.
- Colon cancer: the new Breast cancer.
- NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.
- NCCN task force report: management of neuropathy in Cancer.
- Case records of the Massachusetts General Hospital. Case 25-2009. A 36-year-old woman with hormone-receptor-positive Breast cancer.
- Quality measures, clinical practice, NCCN, and McAllen, Texas.
- Do clinical trials belong in clinical guidelines?
- By the way, doctor. I've been having PET-CT scans to look for any growth or spread of previously removed tumors. Are they as reliable in detecting Breast cancer as a r...
- SPIKES for difficult conversations with Cancer patients.
- Personalized medicine and Breast cancer care.
- Self-reported practices and attitudes of US oncologists regarding off-protocol therapy.
- VEGF as a marker for outcome among advanced Breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.
- Improving tolerance of AIs: predicting risk and uncovering mechanisms of musculoskeletal toxicity.
- Conflict of interest and oncology guidelines.
- Oncology teamwork.
- NCCN Task Force Report: mTOR inhibition in solid tumors.
- Lymphopenia associated with adjuvant anthracycline/ taxane regimens.
- Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal Breast cancer: a modeling analysis.
- Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive Breast cancer.
- Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic Breast cancer previously treated with an anthracycline...
- Preoperative therapy as a model for translational research in Breast cancer.
- Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage Breast cancer.
- Preoperative therapy in invasive Breast cancer: pathologic assessment and systemic therapy issues in operable disease.
- Molecular origins of Cancer.
- NCCN Task Force Report: Breast cancer in the older woman.
- Aromatase inhibitors and arthralgias: a new frontier in symptom management for Breast cancer survivors.
- Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic Breast cancer: the trastuzumab and vinorelbine or taxane study.
- Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic Breast cancer: unexpected incidence of hypersensitivity reactions.
- NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in Cancer.
- Anemia in cancer: update on studies of erythropoiesis-stimulating agents.
- Chemotherapy for metastatic Breast cancer.
- Rebeccamycin analog for refractory Breast cancer: a randomized phase II trial of dosing schedules.
- Biological basis of Breast cancer: an introduction.
- Novel approaches to advanced Breast cancer: bevacizumab and lapatinib.
- Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early Breast cancer.
- Myeloid growth factor support for dose-dense adjuvant chemotherapy for Breast cancer.
- Pneumocystis carinii pneumonia during dose-dense chemotherapy for Breast cancer.
- The role of angiogenesis inhibition in the treatment of Breast cancer.
- The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage Breast cancer: a decision analysis.
- Inadvertent use of aromatase inhibitors in patients with Breast cancer with residual ovarian function: cases and lessons.
- Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III Breast cancer.
- Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant Breast cancer chemotherapy.
- The distinctive nature of HER2-positive Breast cancers.
- Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage Breast cancer: a decision analysis.
- HER2 or not HER2: that is the question.
- American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-posit...
Schools
Harvard Medical School
Massachusetts General Hospital
Dana Farber Cancer Institute
Brigham and Women39s Hospital
Harvard Med School
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Breast Cancer
- Carcinoma in Situ
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Boston Magazine
- Fellow (FASCO)
- Whos Who in Medicine and Healthcare
- Super Doctor
Education
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Harvard Medical School
Hospital
-
Massachusetts General Hospital -
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1285603001 | |
| NPPES Provider LastName | BURSTEIN | |
| NPPES Provider FirstName | HAROLD | |
| NPPES Provider ZIPCode | 02115 | |
| NPPES Provider State | MA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 203.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1285603001 |
| Last Name Of The Provider | BURSTEIN |
| First Name Of The Provider | HAROLD |
| View All |
Similar Doctors
|
|
Dr. Robert L. Schlossman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas J. Schuetz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James A. Decaprio, MD |
|
|
Dr. Nikolaos Trikalinos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Margaret A. Shipp, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William C. Hahn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pasi A. Janne, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ian E. Krop, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Irene M. Ghobrial, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John G. Krikorian, MD
This Doctor is OpenDoctor Recommended.
|